Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects

This study has been completed.
Information provided by:
AstraZeneca Identifier:
First received: May 22, 2008
Last updated: December 8, 2010
Last verified: December 2008
The purpose of this study is to investigate the safety and tolerability of AZD2066 using multiple escalating dose panels. There will be separate panels for young healthy volunteers and elderly healthy volunteers. Each panel will contain 10 volunteers who will randomly receive AZD2066 or placebo. One panel will be run at a time with a fixed dose given. After the completion of each panel, a Safety Review Committee will decide if the study can proceed to the next dose panel.

Condition Intervention Phase
Drug: AZD2066
Drug: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: A Phase I, Single-centre, Randomised, Double-blind, Parallel Group, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects After Oral Multiple Ascending Doses

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Safety and tolerability of AZD2066 by assessment of vital signs, laboratory variables and ECG [ Time Frame: Assessments taken at visit 1 (enrolment), defined time points pre dose and post dose during visit 2 (residential period): days -1 through to day 15 and follow up visit 3 ]

Secondary Outcome Measures:
  • Safety and tolerability of AZD2066 by assessment of adverse events [ Time Frame: Non serious adverse events will be collected from the start of Visit 2 until the end of the study. Serious adverse events will be collected from signing of consent until end of study. ]
  • Investigate PK profile (including dose proportionality, degree of accumulation and time dependancy) of AZD2066 (and possible relevant metabolites). [ Time Frame: PK sampling taken at defined timepoints during residential period and follow-up. ]
  • Investigate CNS effects of AZD2066 [ Time Frame: Psychometric test battery performed at defined timepoints during the residential period. Test on day -1 for training purposes. ]

Enrollment: 110
Study Start Date: January 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Oral solution.
Drug: AZD2066
Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
Placebo Comparator: 2
Oral solution
Drug: Placebo
Administered orally as a solution once per day on day 1, and then day 3 through to day 12.


Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of signed informed consent
  • Clinically normal physical findings and laboratory values as judged by the investigator and a normal resting ECG.

Exclusion Criteria:

  • History of somatic disease/condition, which may interfere with the objectives of the study, as judged by the investigator.
  • History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, borderline state and personality disorder.
  • Intake of medicine (except occasional paracetamol or nasal spray) within first 2 weeks before first administration of study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00684502

Research Site
Stockholm, Sweden
Sponsors and Collaborators
Principal Investigator: Bo Fransson, MD AstraZeneca R&D SödertäljeMedical Science, CPU C2:84Karolinska University Hospital HuddingeSE-141 86 Stockholm, Sweden
Study Chair: Lars Stahle, MD, PhD AstraZeneca R&D Södertälje Medical Science S-151 85 Södertälje Sweden
  More Information

Responsible Party: Rolf Karlsten, M.D., Medical Science Director, Emerging Neuroscience, AstraZeneca Pharmaceuticals Identifier: NCT00684502     History of Changes
Other Study ID Numbers: D0475C00002
EudractCT 2007-005524-33
Study First Received: May 22, 2008
Last Updated: December 8, 2010

Keywords provided by AstraZeneca:
Pain conditions

Additional relevant MeSH terms:
Pharmaceutical Solutions processed this record on May 25, 2017